Vaxil BioTherapeutics

Developing Cancer and Tuberculosis Vaccines

Health Tech & Life Sciences
Public on TASE on Mar 2016

Company Overview

Snapshot

Founded in February 2007, Vaxil BioTherapeutics operates with 1–10 employees. The company has raised a total of $6.35M across four funding rounds from two investors. In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data for a proposed reverse takeover.

Business overview

Vaxil BioTherapeutics is a clinical-stage company focused on developing immunotherapeutic products, including long peptide vaccines and antibodies, to treat cancer and infectious diseases. Its core technology, VaxHit, utilizes signal peptide domains in selected targets as core antigens. The company's lead product, ImMucin, has received EMA and FDA orphan drug designation for multiple myeloma and has completed a Phase 1/2 clinical trial. Vaxil also develops SPmAb-2.1 and SPmAb-6, anti-MUC1 SP antibodies, and MTBuVax, a vaccine against mycobacterium tuberculosis, serving the pharmaceutical and biotechnology sectors within the Health Tech & Life Sciences industry.

Strategic signal

In May 2024, Vaxil Bio announced a Letter of Intent with Green Data for a proposed reverse takeover. This strategic move signals a potential shift in the company's corporate structure and future direction, indicating a significant development for investors and innovation teams to monitor as it could lead to new opportunities or a re-evaluation of the company's market position.

Company Intelligence Q&A

What was a significant corporate development for Vaxil Bio in 2024?
In May 2024, Vaxil Bio entered into a Letter of Intent with Green Data concerning a proposed reverse takeover, indicating a potential change in corporate control and strategic direction for the company.
What was the outcome of Vaxil's CorVax in vivo study?
In September 2020, Vaxil announced positive results from its CorVax in vivo study, demonstrating progress in its vaccine development efforts.
When did Vaxil initiate a pre-clinical study in a new oncology target?
In October 2020, Vaxil initiated a pre-clinical study focused on a new oncology target, expanding its research pipeline in cancer treatment.
Has Vaxil BioTherapeutics received any patents for its immunotherapy treatments?
In May 2018, Vaxil BioTherapeutics was granted its 9th patent for an immunotherapy treatment, highlighting its ongoing innovation and intellectual property development in the field.
What was Vaxil's activity regarding a COVID-19 vaccine in early 2020?
In March 2020, Vaxil commenced preclinical trials for a COVID-19 vaccine and filed an additional patent application related to its COVID-19 research.

External links